cancer treatment

A new study explains how the loss of genetic material on the Y chromosome may drive cancer development in men. Researchers say age-related loss of parts of the Y chromosome can impair tumour suppression, potentially explaining why certain cancers affect men more severely. The findings could point to new biomarkers and treatment approaches.

Researchers report observing how an aggressive brain cancer physically remodels brain tissue as it grows, offering a live view of tumor progression. The findings shed light on how deadly brain tumors invade and distort surrounding structures, which could inform future treatment approaches. The work is drawing attention for its striking visualization of the disease's effects on the brain.

A new report outlines how biological research is changing the way breast cancer is diagnosed and treated. Understanding tumour biology is increasingly guiding treatment choices, moving care away from one-size-fits-all approaches toward therapies matched to the specific characteristics of each patient's cancer. The piece has drawn attention from clinicians and patient advocates following shifts in treatment standards.

Coverage is circulating of the second part of a highlights roundup from the World Cancer Congress 2026, summarising key presentations and developments shared at the global oncology gathering. The roundup is aimed at cancer professionals and researchers following the congress remotely, distilling sessions into digestible takeaways. Interest centres on what new research, treatment approaches and policy discussions were featured at this year's event.

Researchers led by Dr. Jona Kayser at MPZPM report that physical processes within dense cell populations strongly influence the optimal timing of treatment cycles in cancer and antibiotic therapy. Treatment resistance is a central obstacle in both fields, and the findings suggest that scheduling therapies around these dynamics could improve outcomes. The work, associated with the Max Planck Institute for the Science of Light, points to a greater role for biophysics in designing treatment schedules.

NPR has published the story of a professor who was diagnosed with lung cancer and underwent cutting-edge treatment, reportedly involving mRNA-based approaches and questions of affordability. The piece follows his shift from expert observer to patient navigating new therapies. It is drawing attention as a personal account of where lung cancer treatment stands and who can access it.

Biotech company Vyriad has begun the first-in-human clinical trial of VV169, an in vivo CAR T therapy that engineers immune cells inside the patient's body rather than in a lab. The early-stage trial marks a first step in testing the safety of the experimental cancer treatment in people, an approach watched closely as it could simplify a cell therapy process that is currently complex and costly.

Researchers have highlighted three previously overlooked RNA molecules as potential new markers for colorectal cancer. The findings suggest these molecules could help detect the disease earlier and guide treatment choices, offering a possible addition to existing screening and diagnostic tools. Colorectal cancer remains one of the most common cancers worldwide, so any lead on earlier detection is drawing scientific and media attention.

A New York Times opinion piece asks why clinical trials for cancer drugs take so long, examining delays in the process of testing new treatments on patients. The article prompts discussion about whether trial design, regulatory requirements, or patient recruitment are the main bottlenecks in getting promising cancer therapies to people faster.

Researchers describe a 'proliferative pause' — a period when cancer cells spreading to the brain stop dividing before reactivating — and suggest this dormant phase could be a critical treatment window to stop brain metastases before they take hold. Targeting cells during this pause may prevent lethal secondary brain tumours in cancers prone to spreading there.

Volunteers and advocates with the American Cancer Society's Cancer Action Network visited Capitol Hill to meet with members of Congress, urging support for cancer research funding and patient-focused legislation. The advocacy day brings grassroots concerns about prevention, treatment access, and federal research investment directly to lawmakers, and is part of the organization's ongoing effort to keep cancer policy on the national legislative agenda.

Researchers report that biological features of prostate tumours can help determine which patients are most likely to benefit from hormone therapy. By profiling tumour biology, doctors may be able to better target treatment and avoid giving hormone therapy to those unlikely to respond, a step toward more personalised prostate cancer care.

Dr. Ilyas Sahin has drawn attention to a new scientific study on colorectal cancer liver metastasis, one of the most common and difficult sites of colorectal cancer spread. The findings are being shared among oncology watchers interested in how the disease progresses and what new treatment approaches might follow.

UT Health San Antonio is working to find a cure for liver cancer, a disease affecting communities across South Texas at elevated rates. The health institution's research efforts were highlighted in local coverage, drawing attention to the region's particular vulnerability and the push for better treatments.